The Jak1/Jak2 Inhibitor Momelotinib Inhibits Alk2, Decreases Hepcidin Production and Ameliorates Anemia of Chronic Disease (ACD) in Rodents

被引：7
|
作者：
Asshoff, Malte [1 ]
Warr, Matthew [2 ]
Haschka, David [1 ]
Tymoszuk, Piotr [1 ]
Petzer, Verena [1 ]
Demetz, Egon [1 ]
Maciejewski, Pat [2 ]
Seifert, Markus [1 ]
Nairz, Manfred [1 ]
Posch, Wilfried [3 ]
Fowles, Peter [2 ]
Weiss, Guenter [1 ]
Whitney, Andy [2 ]
Theurl, Igor [1 ]
机构：
[1] Med Univ Innsbruck, Internal Med 6, A-6020 Innsbruck, Austria
[2] Gilead Sci, Branford, CT USA
[3] Med Univ Innsbruck, Divsison Hyg & Med Microbiol, A-6020 Innsbruck, Austria
来源：
BLOOD | 2015年 / 126卷 / 23期
关键词：
D O I：
10.1182/blood.V126.23.538.538
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [31] IMPLICATIONS OF RUXOLITINIB, JAK1/JAK2 INHIBITOR, ON THE GRAFT EFFECT AGAINST LEUKEMIA IN NK CELLS
    Carmen, Mestre-Duran
    Carla, Martin-Cortazar
    Al-Fonso, Navarro-Zapata
    David, Bueno
    Laura, Clares-Villa
    Alicia, Pernas
    Karima, Al-akioui
    Luisa, Sisinni
    Blanca, Garcia-Solis
    Victor, Galan
    Nerea, Matamala
    Adela, Escudero
    Cristina, Ferreras
    Antonio, Perez-Martinez
    HAEMATOLOGICA, 2021, 106 (10) : 29 - 30
  • [32] Resolution of bone marrow fibrosis in a patient receiving JAK1/JAK2 inhibitor treatment with ruxolitinib
    Wilkins, Bridget S.
    Radia, Deepti
    Woodley, Claire
    El Farhi, Sarah
    Keohane, Clodagh
    HAEMATOLOGICA, 2013, 98 (12) : 1872 - 1876
  • [33] Jaktinib (JAK1/2 inhibitor): A momelotinib derivative with similar activity and optimized dosing schedule
    Tefferi, Ayalew
    Gangat, Naseema
    Pardanani, Animesh
    AMERICAN JOURNAL OF HEMATOLOGY, 2022, 97 (12) : 1507 - 1509
  • [34] Ruxolitinib, a JAK1/JAK2 Selective Inhibitor, Ameliorates Gastrointestinal and Cutaneous Pathogenesis in MHC-Mismatched Preclinical Models of Acute and Chronic Graft-Versus-Host Disease
    Huarte, Eduardo
    Parker, Melissa
    Juvekar, Ashish
    Oliver, Julian
    Yao, Wenqing
    Smith, Paul
    BLOOD, 2019, 134
  • [35] In vivo activity of SGI-1252, a potent, small-molecule dual inhibitor of JAK2 and ALK2
    David, Vollmer
    Bearss, Jared
    Jones, Carissa
    McCarthy, Virgil
    Gourley, Eric
    Liu, Xiao-Hui
    Vankayalapati, Hariprasad
    Warner, Steven
    Olsen, Colin
    Bearss, David
    MOLECULAR CANCER THERAPEUTICS, 2009, 8 (12)
  • [36] The JAK1/JAK2-inhibitor ruxolitinib inhibits mast cell degranulation and cytokine release
    Hermans, Maud A. W.
    Schrijver, Benjamin
    van Holten-Neelen, Conny C. P. A.
    Gerth van Wijk, Roy
    van Hagen, P. Martin
    van Daele, Paul L. A.
    Dik, Willem A.
    CLINICAL AND EXPERIMENTAL ALLERGY, 2018, 48 (11): : 1412 - 1420
  • [37] Topical Application of JAK1/JAK2 Inhibitor Momelotinib Exhibits Significant Anti-Inflammatory Responses in DNCB-Induced Atopic Dermatitis Model Mice
    Jin, Wenyu
    Huang, Wei
    Chen, Liqing
    Jin, Mingji
    Wang, Qiming
    Gao, Zhonggao
    Jin, Zhehu
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2018, 19 (12)
  • [38] Discovery of INCB018424: A potent and selective JAK1/JAK2 inhibitor for the treatment of myeloproliferative neoplasms
    Rodgers, James D.
    Fridman, Jordan S.
    Shepard, S.
    Maduskuie, T. P.
    Arvanitis, A. G.
    Wang, H.
    Shao, L.
    Folmer, B.
    Falahatpisheh, N.
    Rafalski, M.
    Storace, L.
    Jalluri, R. K.
    Vaddi, K.
    Haley, P. J.
    Burn, T. C.
    Rupar, M.
    Liu, P. C.
    Covington, M. B.
    Caulder, E.
    Li, J.
    Waeltz, P.
    Margulis, A.
    Wynn, R.
    Becker-Pasha, M.
    Li, Y.
    Lo, Y.
    Thomas, B.
    Hollis, G.
    Favata, M. F.
    Wen, X.
    Kelly, J.
    Solomon, K.
    Scherle, P. A.
    Shi, J.
    Yeleswaram, S.
    Newton, R. C.
    Friedman, S. M.
    Metcalf, B.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2010, 240
  • [39] Phase I/II Study of CYT387, a JAK1/JAK2 Inhibitor for the Treatment of Myelofibrosis
    Pardanani, Animesh
    Gotlib, Jason
    Gupta, Vikas
    Roberts, Andrew W.
    Wadleigh, Martha
    Sirhan, Shireen
    Bavisotto, Linda M.
    Kawashima, Jun
    Kowalski, Mark
    Tefferi, Ayalew
    BLOOD, 2012, 120 (21)
  • [40] A phase II study of the oral JAK1/JAK2 inhibitor ruxolitinib in advanced relapsed/refractory Hodgkin lymphoma
    Van den Neste, Eric
    Andre, Marc
    Gastinne, Thomas
    Stamatoullas, Aspasia
    Haioun, Corinne
    Belhabri, Amine
    Reman, Oumedaly
    Casasnovas, Olivier
    Ghesquieres, Herve
    Verhoef, Gregor
    Claessen, Marie-Jose
    Poirel, Helene A.
    Copin, Marie-Christine
    Dubois, Romain
    Vandenberghe, Peter
    Stoian, Ioanna-Andrea
    Cottereau, Anne S.
    Bailly, Sarah
    Knoops, Laurent
    Morschhauser, Franck
    HAEMATOLOGICA, 2018, 103 (05) : 840 - 848
12345